glp 1 pet scan GLP-1 receptor targeting using 68 Ga-DOTA-exendin-4. Patient with Forward Look Archives | Cancer

SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM ): mean weight loss of 15.0%, 19.5%, and 20.9% respectively over 72 weeks, versus 3.1% on placebo

Distribution of aberrant Glx signals in bipolar disorder also substantially overlaps with glial alterations reported in the post-mortem cytological studies

Lactylation, a novel PTM driven by the metabolic byproduct lactate, operates as a dynamic regulatory mechanism that links cellular metabolism with epigenetic processes

Maintenance is part of the plan

Topical copper peptides offer an alternative with different risk profiles

Rheumatological irAEs are not commonly reported as signature irAEs in patients receiving immunotherapy